The European Medicines Agency has granted marketing authorization for the anti-HIV medication INTELENCE™ (etravirine), the first next generation non-nucleoside reverse transcriptase inhibitor (NNRTI) to show efficacy in patients with NNRTI-resistant HIV. Also known as TMC125, Intelence was developed by Tibotec Pharmaceuticals, Ltd. Janssen-Cilag International NV will hold the marketing authorization. It has the potential to suppress the virus to undetectable levels. Intelence, along with a boosted protease inhibitor and other antiretroviral medicinal products, is indicated for the treatment of HIV type 1 infection in adult patients with experience of antiretroviral treatment. The recommended oral dose of Intelence tablets is 200 mg (two 100mg tablets) twice daily following a meal.